Madopar Cr (Benserazide, Levodopa)

Levodopa is a precursor of dopamine that crosses the blood‑brain barrier. Once inside the central nervous system, it is converted into dopamine, directly replenishing the neurotransmitter that is deficient in Parkinson's disease. This increase in dopamine improves motor control and reduces characteristic Parkinsonian symptoms.

The dose of Madopar CR is individualized for each patient. A qualified prescriber determines the appropriate starting dose, titration schedule, and maintenance dose based on the patient's clinical response, disease severity, and tolerability. Specific dosing regimens should be obtained from the prescribing clinician.

Safety of Madopar CR during pregnancy and lactation has not been established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the Madopar CR product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Madopar CR provides a controlled‑release delivery that maintains steadier plasma levodopa concentrations over several hours, potentially reducing dosing frequency and minimizing peaks and troughs associated with immediate‑release tablets. This can lead to smoother symptom control and may lessen the occurrence of motor fluctuations in some patients.

Madopar CR tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct light, and ensure the container is tightly closed to maintain tablet integrity throughout its shelf life.

Madopar CR is taken orally. The tablet should be swallowed whole with a glass of water and not chewed, crushed, or split, as altering the tablet can disrupt the controlled‑release mechanism and affect drug absorption.

Serious adverse reactions include hallucinations or psychosis, severe hypotension that may cause fainting, cardiac arrhythmias, and rare anaphylactic reactions. Patients should seek immediate medical attention if they experience sudden confusion, severe dizziness, palpitations, or signs of an allergic response.

Madopar CR is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients of the tablet. It should also be avoided in individuals taking non‑selective MAO inhibitors, or in those with narrow‑angle glaucoma, malignant melanoma, or severe cardiovascular disease without careful medical supervision.